Trial
NCT03259425
Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Utah
Collaborators
Bristol-Myers Squibb; Takara Bio Inc.
Condition
Melanoma
Intervention
Nivolumab
Why stopped
DSMC Recommendation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-13